Introduction
Liver cirrhosis (LC) is a worldwide problem. In North America and Europe, the prevalence is approximately 1000 per million population, and mortality is approximately 100 per million, which is also the case in Japan. [1] [2] [3] Among many etiological factors such as hepatitis virus infection, alcohol and drug abuse, chronic infection by the hepatitis C virus (HCV) is the major cause of LC in Japan and in some southern European countries such as Italy and Spain. HCV-carrier frequency is estimated at 2% worldwide, and chronic hepatitis C progresses to LC and then hepatocellular carcinoma at a high incidence within two or three decades.
While several therapeutic approaches have been investigated for HCV infection, such as iron reduction, antioxidants and antiviral agents (Amantadine, Ribavirin), 4 the most effective therapy is currently considered to be IFN treatment. 2, 5, 6 Among interferons (IFNs), IFN-a and IFN-b are widely used to treat HCV infection in clinics, whereas IFN-g does not have a significant antiviral effect. In addition to the antiviral effect, several lines of evidence suggested that IFN-a is also effective in curtailing LC in experimental animal models and clinical studies. [6] [7] [8] [9] [10] [11] [12] [13] IFN-a is therefore expected to be particularly powerful in preventing the development of LC in patients with HCV infection.
In the conventional IFN regimen, the recombinant IFN-a protein is subcutaneously injected for several months. However, the overall sustained virologic response rate is still limited to 20-30%. 2, 6 Although dose escalation is expected to be effective in a resistant case, 6 it is often impossible because of the severe adverse effects such as flu-like symptoms, leukopenia and mental depression. Since the half-life of the IFN-a protein is 3 h in the blood circulation and only 0.01% of subcutaneously injected IFN-a can reach the target organ (the liver), 14 the administration of IFN-a through a subcutaneous route requires higher IFN-a levels in the serum than in the liver. Therefore, vector-mediated local IFN-a production in the liver may be able to overcome the limitations of conventional IFN-a protein therapy.
In this study, we examined whether a gene therapy strategy of targeting IFN-a gene expression to the liver can be a better alternative to conventional IFN-a protein administration to the subcutaneous space with respect to the distribution of the IFN-a protein, period of expression and development of any adverse effect. An adenovirus vector was employed, since intravenous injection of the vector could express transgenes efficiently in the liver, 15 and the biological effect of the adenovirus-mediated IFN-a gene therapy was also evaluated in rats with dimethylnitrosamine (DMN)-induced LC. [16] [17] [18] This model showed the confinement of the IFN-a expression to the liver and the therapeutic efficacy of suppressing liver injury and fibrosis. Moreover, we demonstrated the usefulness of the Cremediated regulation system for shutting off the IFN-a transgene expression efficiently in vitro and in vivo. The study suggests for the first time the feasibility of IFN-a gene therapy for HCV-associated liver diseases.
Results

Intravenous adenovirus vector injection into rats with DMN-induced cirrhotic liver
In rats with DMN treatment for 3 weeks, all liver specimens from 14 rats, which were killed for examination of LC development (n¼5) and vector distribution (n¼9), showed the collapse of parenchymal cells and the formation of regenerative nodules separated by extensive fibrous septa, which are similar to the characteristic pathological changes observed in human LC (Figure 1a) . To examine the adenovirus-mediated gene transduction efficiency into the liver, AxCA-lacZ or ADVCA-AP was intravenously injected into rats with DMN-induced LC. The expression of lacZ and AP genes was mainly observed in the liver, especially in septal cells but not in the hepatocytes (Figure 1c and inset) . 15 Except for a faint expression in the spleen and kidney, X-gal staining was not detected in major organs such as the lung, heart, small intestine and testis. To confirm the preferential transgene expression in the liver, we examined the lacZ gene expression in various organs of cirrhotic rats transduced with AxCA-lacZ by the RT-PCR method. 7 PFU) ( Â 400). P, parenchyma; S, fibrous septa. Brown-stained cells were observed in fibrous septa. X-gal and AP staining was performed as described. 47, 49 (e) RT-PCR analysis of organ distribution of lacZ gene expression 2 days after the intravenous injection of AxCA-lacZ. The untreated normal liver did not show any PCR band.
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The expression of the lacZ gene was mainly observed in the liver, and faint expression was detected in the lung, kidney and small intestine (Figure 1e ). In normal rats injected with saline, X-gal staining was detected in septal cells as well as in hepatocytes of the liver (Figure 1d ) and faint staining was observed in the spleen. The lacZ gene expression data were consistent with the immunostaining of IFN-a in the rats with DMN-induced LC or normal rats after the injection of AxCA-rIFN (data not shown).
IFN-a levels in the liver and serum following AxCA-rIFN injection
Based on in situ evidence suggesting the preferential expression of INF-a in the liver, the IFN-a levels and time course of its clearance were measured in the liver and serum following the intravenous injection of AxCA-rIFN. In total, 120 IU of the rat IFN-a per gram of tissue was produced in the liver of DMN-injected rats 3 days after the injection of AxCA-rIFN, whereas no IFN-a was detected in the serum (Figure 2 ). On the other hand, a significant level of rat IFN-a transiently appeared in the liver and in the serum as well by the subcutaneous injection of 1 Â 10 5 IU of the recombinant rat IFN-a (Figure 2 ), which corresponds to the dose range of conventional IFN-a treatment in clinics. To assess the toxicity of the adenovirus-mediated IFN-a gene therapy, hepatic transaminases were measured in DMN-injected rats 2 days after the injection of AxCA-rIFN 
Improvement of LC in DMN-treated rats by intravenous injection of AxCA-rIFN
We examined whether hepatic INF-a expression could improve liver fibrosis in a DMN-injected rat, because the antifibrotic effect of IFN-a protein has been shown in experimental animal models and clinical studies. [6] [7] [8] [9] [10] [11] [12] [13] The AxCA-rIFN-treated rats survived significantly longer than the rats injected with either AxCA-lacZ or PBS (P¼0.0001), and five of nine IFN-a-transduced rats survived more than 100 days ( Figure 3 ). Histological examination clearly revealed less fibrous connective tissue components in Glisson's sheath and pseudolobule formations in the livers of control and AxCA-rIFNtransduced rats than in the liver of the AxCA-lacZtransduced rats, in which the extensive formation of fibrotic septa and thickened reticulin fibers joining central areas were observed ( Figures 1a, 4a and b) . The collagens were detected by Sirius red staining 19, 20 in the bridging fibrous septa in the liver of AxCA-lacZtransduced rats, whereas the liver of AxCA-rIFNtransduced rats was almost devoid of collagens ( Figure  4c and d) . The expression of a-smooth muscle actin was reduced in the activated stellate cells of the DMN-treated rats transduced with AxCA-rIFN (Figure 4e and f). To quantitatively assess the liver fibrosis, we measured the hydroxyproline content of the liver 21 and serum levels of transaminases (AST and ALT). The hydroxyproline and transaminases in AxCA-rIFN-treated rats 70 days after the injection were significantly lower than those in AxCA-lacZ-or PBS-injected rats 10 days after the injection (Table 1) . Since it is known that the DMNinduced histopathological changes and hepatic transaminase elevation do not regress spontaneously in the rat LC model, 16, 18, 22 our observation suggested that IFN-a Adenovirus-mediated IFN gene therapy for LC in rat K Suzuki et al gene expression can rescue the rats from DMN-induced hepatic damage and improve the histopathology of LC.
Expression of MMPs and TGF-b in the liver transduced with AxCA-rIFN
To examine the antifibrotic action of IFN-a gene therapy, the expression of metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMP) related to matrix degradation during liver fibrosis was analyzed by the RT-PCR method ( Figure 5 ). Interstitial collagenase (MMP-13) has been considered an essential enzyme for collagenolysis in liver fibrosis, and it was reported that expression of MMP-13 is elevated at peak fibrosis and drops rapidly in the recovery periods. 23, 24 The MMP-2, which is stimulated by TGF-b, is necessary for proliferation and infiltration of hepatic stellate cells in the process of fibrosis formation. [25] [26] [27] The expression of TIMP-1 Adenovirus-mediated IFN gene therapy for LC in rat K Suzuki et al increases in the process of liver fibrosis to promote progression of liver fibrosis by preventing degradation of secreted collagens and decreases in the recovery phase. 28 In this study, the expression of MMP-13, MMP-2 and TIMP-1 was downregulated in the liver treated with AxCA-rIFN compared with the PBS-or AxCA-lacZinjected cirrhotic liver, supporting the antifibrotic action of the AxCA-rIFN. Furthermore, since it is reported that overexpression of TGF-b plays a pivotal role in the progression of fibrosis, 9 we examined TGF-b expression in the liver. The control value of TGF-b in untreated normal rats was 5.571.0 ng/ g (n¼5). Among the rats with DMN-induced LC, AxCArIFN-transduced animals showed a lower TGF-b expression level (40.277.4 ng/g) than did the PBS-injected rats (71.376.0 ng/g). TGF-b immunoreactivity was detected in the liver of an AxCA-lacZ-transduced rat, showing evidence of LC, and by contrast, TGF-b was not detected in the AxCA-rIFN-transduced rat (data not shown). The data suggested that IFN-a gene transfer suppresses TGFb induction in the process of DMN-induced hepatic fibrogenesis.
Regulation of IFN-a expression by Cre-loxP reaction
Although not apparent in our rat experiment, it is known from clinical experience that IFN protein treatment may cause acute adverse effects. Thus, to examine a shut-off system of IFN-a expression based on the Cre recombinase-loxP reaction in the adenovirus vector, an adenovirus vector harboring the rIFN-a gene between two loxP sites (AxCALNL-rIFN) was constructed (Figure 6a) . The intravenous injection of AxCALNL-rIFN was able to produce approximately 120 IU/g of IFN-a in the liver similar to the AxCA-rIFN injection (Figures 2 and 6d) , suggesting both vectors have equal potential for treating cirrhotic liver. First, NBT-2 cells were transfected with AxCALNL-rIFN, and 2 days later a 100 times larger amount of an adenovirus vector expressing the Cre recombinase (AxCAN-Cre) was added to the culture medium to excise the IFN-a gene from AxCALNL-rIFN DNA. As shown in Figure 6b , the 783 bp vector fragment containing the rat IFN-a gene disappeared, and the loxPflanked excised fragment (225 bp) was detected by PCR analysis in NBT-2 cells only after the treatment of AxCAN-Cre. Rat IFN-a production was also significantly suppressed in the NBT-2 cells in vitro by the treatment of AxCAN-Cre ( Figure 6c) .
Next, normal rats were sequentially transduced via the tail vein, first with AxCALNL-rIFN and then 2 days later with AxCAN-Cre. Rat IFN-a expression was again significantly decreased in the liver of the rats injected with AxCAN-Cre as compared to the rats without AxCAN-Cre injection (Figure 6d ).
Discussion
Among preclinical models of liver fibrosis, those induced by the chronic carbon tetrachloride (CCl 4 ) intoxication or ligation of bile duct are often used. However, the reversibility of hepatic fibrosis has been reported in these models. 24 Therefore, we employed a DMN-induced model, in which fibrosis and hepatic transaminase elevation do not spontaneously regress in rat LC. 16, 18, 22 This is the first preclinical study demonstrating the advantage and feasibility of IFN-a gene therapy for LC, and the efficacy and safety of the approach need to be reproduced in other LC models in different animals.
Several strategies have been recently proposed for the gene therapies of LC: a blockade of TGF-b signaling using the dominant negative form of the TGF-b receptor prevented liver fibrogenesis and dysfunction; 29 transduction with hepatocyte growth factor (HGF) gene inhibited fibrogenesis and hepatocyte apoptosis in cirrhotic liver; 30 and an adenovirus-mediated expression of telomerase RNA and urokinase-type plasminogen activator also exerted inhibitory effects against fibrogenesis. 31, 32 However, none of those strategies has been examined for an antiviral effect on HCV. We found that the AxCA-rIFN vector inhibited HCV replication in vitro (unpublished data), and the anti-HCV effect may add an advantage to the IFN-a gene therapy for HCV-induced LC. It is also noted that HGF transgenic mice developed a broad array of tumors, suggesting caution should be used when considering HGF as a future therapeutic agent. 33 The subcutaneous route of IFN protein injection in conventional IFN therapy is often associated with systemic toxicity, because it requires an approximate 14 In this study, we found that an adenovirus-mediated IFN-a gene delivery can lead to a significant IFN-a production in the liver but not in the serum. The locally produced IFN-a will rapidly bind to the receptor in the liver tissue, and only a few IFN-a may escape to the systemic circulation. We detected no significant systemic toxicity in the rats after injection of AxCA-rIFN. Moreover, Figure 2 suggested that a single injection of the IFN-a vector led to a more sustained IFN-a level and a larger area under the concentration curve than did the subcutaneous injection of the IFN-a protein. The cost of the standard IFN regimen in Japan is about 2 million yen (approximately 15 000 US dollars) per patient for 6 months under the Current National Health Insurance Program, which also limits access to therapy for patients who need more IFN because of a significant amount of virus in the serum. The IFN-a gene therapy may offer a better cost-benefit than the conventional IFN protein therapy.
Since it is known from clinical experience that IFN protein treatment may cause acute adverse effects, a safety device should be considered so that vectorinduced IFN-a production can be terminated when a significant adverse effect appears. Several regulatory systems have been proposed for gene transfer: prokaryotic repressor-operator-based approaches (lac, tet) were applied to transgenic mice to control certain gene expression, and recently, a chemically induced dimerization-based approach (FKBP) was shown to be useful for in vivo gene regulation because of its high induction ratio. Among these methods, the Cre-loxP system has an advantage in its simplicity: only a Cre-expressing adenovirus vector is necessary to shut off the gene. To the best of our knowledge, this report is the first to demonstrate that a Cre-mediated regulation system is useful for shutting off gene expression in a gene therapy model in vivo.
Several delivery systems for targeting the liver were reported. Eto and Takahashi 34 reported that hepatitis B virus production was inhibited by asialoglycoprotein receptor-directed IFN, and Protzer et al 35 demonstrated that IFN gene transfer by a hepatitis B virus vector efficiently suppressed wild-type virus replication in a duck model of hepatitis B virus infection. However, the hepatitis B virus vector has a low gene transfer efficiency in the liver as compared with that of an adenovirus. When adenovirus vectors were systemically injected into rodents with normal liver, 80-90% of the vector is found in the liver and most vectors target hepatocytes. 36, 37 Several reports showed that adenovirus-mediated transgene expression was preferentially shown in septal cells rather than in hepatocytes in cirrhotic rats, 15, 38, 39 and Nakamura et al 15 have hypothesized that the reduction of intralobular hemodynamics by the shunt formation between portal and central veins resulted in the shift of Adenovirus-mediated IFN gene therapy for LC in rat K Suzuki et al gene expression from hepatocytes to septal cells in cirrhotic rats. In this study also, the expression of lacZ and AP genes was mainly detected in the fibrous septa of cirrhotic liver after the intravenous injection of vectors. Therefore, an adenovirus might be particularly suitable for gene therapy for LC, because it has a high efficiency of gene transduction into the connective tissues of fibrous septa by the systemic injection. A major concern regarding the adenovirus vectors is their immunogenicity, because a repeated injection of the vector may be necessary to eradicate HCV infection. Adenoviral proteins can induce a toxic/anaphylactic reaction, which seems to depend on the amount of adenovirus vectors. 40, 41 In our strategy, a large amount of adenovirus vector may not be required, because cytokines such as IFN are effective in a small dose. In fact, in this study the injection of 1 Â 10 7 PFU (compatible with 2 Â 10 9 PFU in human) AxCA-rIFN resulted in significant IFN-a production in the rat liver, a level comparable to that produced by subcutaneous injection of 100 000 IU of recombinant IFN-a protein. The intrahepatic arterial infusion, instead of a systemic administration, could further reduce the amount of adenovirus vectors. Less immunogenic vectors such as the 'gutless' adenoviral vector [42] [43] [44] and polycation-based synthetic nonviral vectors 45 are being developed in several laboratories at a rapid pace. The present study showed the feasibility and potential advantages of IFN-a gene therapy for HCVassociated liver diseases.
Materials and methods
Replication-defective recombinant adenoviruses
Replication-defective recombinant adenoviral vectors carrying either rat IFN-a cDNA (AxCA-rIFN), b-galactosidase (AxCA-lacZ) or alkaline phosphatase (ADVCA-AP) gene were prepared as described. 46, 47 The recombinant adenoviruses are Ad5 defective with a deletion in the E3 region and have the CAG promoter, which is a hybrid of the cytomegalovirus immediate-early enhancer sequence and the chicken b-actin/rabbit b-globin promoter. 48 AxCALNL-rIFN, which carries the rat IFN-a cDNA between two loxP sequences downstream of the CAG promoter, was constructed to regulate the IFN-a expression by Cre-lox reaction (Figure 6a) .
Animal model
As a model of LC, we used DMN-injected LC rats, an established animal model of persistent liver fibrosis with pathophysiological findings closely resembling those of human LC. [16] [17] [18] 22 A measure of 1% DMN dissolved in saline was injected into 48 Sprague-Dawley male rats (4-week old, 120-130 g in body weight) intraperitoneally at 1 ml per kg weight for 3 consecutive days per week for 7 weeks. After the DMN injection for 3 weeks, five rats were killed for examination of LC development. Another three rats received subcutaneous injection of the recombinant IFN-a protein. The remaining 40 rats were injected via the tail vein with a single infusion of 200 ml of either PBS (n¼13), 1 Â 10 7 PFU of AxCA-rIFN (n¼12), AxCAlacZ (n¼13) or ADVCA-AP (n¼2). Three rats from each group (ADVCA-AP: n¼2) were killed at day 2 for the analysis of vector distribution. Several organs including the liver, lung, heart, spleen, kidney, small intestine and testis were fixed in 10% formalin for histological examination and histochemical staining of AP or frozen immediately in liquid nitrogen for the measurement of hydroxyproline and TGF-b1, and for the histochemical staining of X-gal. The remaining rats in each PBS-(n¼10), AxCA-rIFN-(n¼9) and AxCA-lacZ-injected group (n¼10) were observed for survival.
Organ distribution of lacZ gene expression
After DMN injection for 3 weeks, the Sprague-Dawley male rats were intravenously injected with 1 Â 10 9 PFU of AxCA-lacZ. Total RNA was extracted 2 days later from various organs such as the lung, heart, liver, spleen, kidney and small intestine using Isogen s reagent (Nippon Gene, Tokyo, Japan) and 2 mg of RNA was used for cDNA synthesis. Amplification of the lacZ cDNA (250 bp) was carried out using 1 ml of synthesized cDNA in a 50 ml PCR mixture containing 20 pmol of the forward primer (5 0 -GATAGATCCCGTCGTTTTAC-3 0 ), reverse primer (5 0 -TGAGGGGACGACGACAGTAT-3 0 ), 1.5 mM MgCl 2 , 0.2 mM dNTPs and 1 U of recombinant Taq DNA polymerase. In total, 30 cycles of the PCR were carried out at 951C for 1 min, 601C for 1 min and 721C for 2 min. The PCR products were electrophoresed on a 2% agarose gel, transferred onto a nylon membrane (Hybond N, Amarsham Biosciences Corp., Piscataway, NJ, USA) and hybridized with a 32 P-labeled lacZ gene in 50% foramide, 5 Â Denhardt's solution, 0.1% SDS, 5 Â SSPE , and 100 mg/ml of salmon testis DNA at 421C for 16 h. The membranes were then washed in 0.1 Â SSC and 0.1% SDS. As a positive control for each RNA preparation and RT-PCR, the glyceraldehydes 3-phosphatase dehydrogenase (G3PDH) sequence was also amplified simultaneously in separate tubes using the forward (5 0 -TGCACCACCAACTGCTTAG-3 0 ) and the reverse primers (5 0 -GGATGCAGGGATGATGTTC-3 0 ). For amplification of G3PDH, PCR was performed for 25 cycles. Rat IFN-a was measured by enzyme-linked immunosorbant assay (ELISA) using anti-rat IFN-a polyclonal antibody (Access Biomedical Diagnostic Research Laboratories Inc., San Diego, CA, USA). TGF-b1 was measured by enzyme assay at a clinical reference laboratory (SRL, Tokyo, Japan). 2 0 -5 0 AS activity was determined by a radioimmunoassay kit (Eiken, Tokyo, Japan).
Immunohistochemical examination
Immunohistochemical analysis was performed using an antibody against rat IFN-a (Access Biomedical Diagnostic Research Laboratories, Inc., a-smooth muscle actin (American Research Product, Tokyo, Japan), or TGF-b1 (Promega, Tokyo, Japan) and developed using ABC kit (Nichirei, Tokyo, Japan).
Expression of MMPs and TIMP
Liver tissues were collected from DMN-treated rats 10 days after the injection of PBS or AxCA-lacZ, and 70 days after the injection of AxCA-rIFN. The expression of MMP-13, MMP-2 and TIMP-1 was examined by the RT-PCR method as described above using the following primer sets: MMP-13, forward (5 0 -TGACTATGCG- Regulation of IFN-a expression by Cre-loxP reaction NBT-2 cells (rat bladder cancer cell line, 1 Â 10 5 cells) were transfected with AxCALNL-rIFN at an moi of 30, and 2 days later the cells were transfected with AxCANCre at an moi of 3000. The Sprague-Dawley rats were transduced with 200 ml of AxCALNL-rIFN (1 Â 10 7 PFU) through the tail vein, and 2 days later AxCAN-Cre (1 Â 10 9 PFU) was transduced via the same route. Two days later, the rats were killed to examine rat IFN-a expression by ELISA. The status of the vector DNA was examined by PCR 2 and 6 days after the injection. The sequences of the forward and reverse primers were 5 0 -GTGGTATTTGTGAGCCAGGG-3 0 , and 5 0 -TACAGCTC-CTGGGCAACGTG-3 0 , respectively (Figure 6a ). In total 35 cycles of the PCR were carried out at 941C for 30 s, 571C for 30 s and 721C for 60 s, and the PCR products were electrophoresed on a 1% agarose gel.
Statistical analysis
Statistical differences between variables were analyzed by the unpaired t-test. Survival distributions were calculated by the Kaplan-Meier method and were analyzed using the log-rank test. P-value o0.01 was considered significant.
